Ticagrelor Removal Study Using CytoSorb® 300 mL Device During CPB in Patients Undergoing Emergent Cardiothoracic Surgery (CyTation)
A Prospective, Open, Multi-center, Single-arm Study to Demonstrate the Feasibility of the CytoSorb® 300 mL Device to Remove Ticagrelor During Cardiopulmonary Bypass in Patients on Ticagrelor Undergoing Emergent Cardiothoracic Surgery
Sponsor: CytoSorbents Europe GmbH
Terminated
Due to Corona pandemic, planned ammount of enrolled patient could not be reached, protocol section Early termination of the study - criterion Difficulties in recruiting patients is fully met-\>recruitment period will not be extended
Other terminated trials from CytoSorbents Europe GmbH
More terminations from CytoSorbents Europe GmbH
Other Acute Coronary Syndrome trials with similar outcome
A NA clinical study on Acute Coronary Syndrome, this trial is terminated or withdrawn. The trial is conducted by CytoSorbents Europe GmbH and has accumulated 9 data snapshots since 2021. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Mar 2022 — Jul 2024 [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Dec 2021 — Mar 2022 [monthly]
Recruiting NA
-
Oct 2021 — Dec 2021 [monthly]
Recruiting NA
▶ Show 4 earlier versions
-
Apr 2021 — Oct 2021 [monthly]
Recruiting NA
-
Feb 2021 — Apr 2021 [monthly]
Recruiting NA
-
Jan 2021 — Feb 2021 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- CytoSorbents Europe GmbH
For direct contact, visit the study record on ClinicalTrials.gov .